2019
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015
Cleveland AA, Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Saadeh K, Pemmaraju M, Higgins K, Ehlers S, Scahill M, Jones M, Querec T, Markowitz LE, Unger ER, Group H. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015. International Journal Of Cancer 2019, 146: 810-818. PMID: 30980692, PMCID: PMC9112013, DOI: 10.1002/ijc.32340.Peer-Reviewed Original ResearchConceptsCervical intraepithelial neoplasiaIncidence rateIncidence trendsAge groupsHuman papillomavirus vaccinationPopulation-based surveillanceHigh-risk typesHuman papillomavirus typesYears age groupGrade 3 casesOlder age groupsCIN3 casesPapillomavirus vaccinationQuadrivalent vaccineCIN3 lesionsHPV typesMedian ageVaccine eraIntraepithelial neoplasiaCervical cancerPrimary preventionCervical adenocarcinomaVaccine preventionCervical precancerPapillomavirus types
2017
Cervical Adenocarcinoma in Situ in the United States: Results from Population-based Laboratory Surveillance, 2008–2014
Cleveland A, Johnson M, Gargano J, Park I, Griffin M, Niccolai L, Schafer S, Bennett N, Markowitz L, Unger E. Cervical Adenocarcinoma in Situ in the United States: Results from Population-based Laboratory Surveillance, 2008–2014. Open Forum Infectious Diseases 2017, 4: s68-s69. PMCID: PMC5632134, DOI: 10.1093/ofid/ofx162.164.Peer-Reviewed Original ResearchNon-vaccine typesHPV typesCervical cancer screening methodsHPV typing resultsL1 consensus PCRHuman papillomavirus vaccinationPopulation-based surveillanceCancer screening methodsChi-square testCIN3 casesPapillomavirus vaccinationHPV typingMedian ageHPV-18Primary preventionCervical adenocarcinomaVaccine preventionPrecursor lesionsAIS casesCIN3Positive specimensHR typesCIN2Disease controlCell precursors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply